Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Scientist I in Clinical Biomarker Development team, within the Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine’s oncology pipeline. You will: Design and execute clinical biomarker strategies to support early response monitoring, patient stratification, and understanding resistance mechanisms. Support biomarker implementation for early- and late-stage oncology clinical trials. Oversee biomarker assay development, qualification, and sample analysis in collaboration with internal teams and external CROs. Analyze and interpret biomarker data in the context of clinical outcomes and present results to cross-functional teams. Contribute to clinical protocols, study reports, and regulatory documents (e.g., INDs, IBs, CSRs). Translate preclinical findings into clinically actionable biomarker hypotheses. Stay current with emerging biomarker technologies and trends in precision oncology.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree